PCSK9 and metabolic syndrome: PCSK9 antibodies (PCSK9i) have also shown effectiveness in reducing cardiovascular events in individuals with coronary artery disease who are intolerant to statin therapy.358 In a small study involving 11 PLWH with dyslipidemia not diagnosed with coronary artery disease and 19 PLWH with nearly optimal or above goal low-density lipoprotein cholesterol levels, the inhibition of PCSK9 with evolocumab demonstrated an improvement in abnormal coronary endothelial function.344 In this study, no improvement was reported in serum inflammation biomarkers.